Pricing Log in Create free account
Saturday 17 October 2026 Export INMB’s income statement to Excel — free account

INmune Bio, Inc.

INMB Healthcare Biotechnology

INmune Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $50,000.00, up 257.1% from fiscal 2024. In the quarter to June 2026, revenue grew 8.70%, EPS grew 95.2% and free cash flow grew 55.4%, each against the same quarter a year earlier.

1.57 0.08 −4.85%
Market cap
$45.8M
P/E
0.0×
Fwd P/E
−1.8×
Dividend yield
—
F-score
4/9
Altman Z
−10.46
Beneish M
−3.67
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

INmune Bio, Inc. (INMB) EV/Sales

Alert me on EV/Sales

As of 16 October 2026, INmune Bio, Inc. (INMB) trades at a EV/Sales of 210×. Over the past ten years it has ranged from 0.0× (December 2021) to 1,506× (April 2024); the current reading is higher than 53% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 139× (76.41%)
FY2024 588× (48.82%)
FY2023 1,150× 419.07%
FY2022 221× (59.23%)
FY2021 543× —
FY2020 0.0× —

Quarterly newest first

Period EV/Sales Change
Mar 2025 1,194× (18.30%)
Mar 2024 1,462× 27.15%
Dec 2023 1,150× 188.00%
Sep 2023 399× (14.30%)
10 more quarters

Against its own ten years

Low 0.0× High 1,506×
Ten-year median 193×
Current reading's percentile 24

EV/Sales against peers

Company EV/Sales
IBIO iBio, Inc. compare −9.7×
KLRS Kalaris Therapeutics Inc. compare n/m
ANVS Annovis Bio, Inc. compare n/m
ALDX Aldeyra Therapeutics, Inc. compare n/m
TVGN Tevogen Inc. compare n/m
IMA ImageneBio, Inc. compare 2.5×
SER Serina Therapeutics, Inc. compare 66.0×
INMB INmune Bio, Inc. 210×
CLNN Clene Inc. compare 239×
Biotechnology industry median 9.2×
Healthcare sector median 3.4×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on INMB